Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease

OBJECTIVE: To estimate the cost-effectiveness of adalimumab plus methotrexate (MTX) versus MTX monotherapy in early, aggressive rheumatoid arthritis (RA) when explicitly modelling short-term (reversible) and long-term (irreversible, ie, joint damage) disease activity and physical function. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephens, Stephanie, Botteman, Marc F, Cifaldi, Mary A, van Hout, Ben A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466612/
https://www.ncbi.nlm.nih.gov/pubmed/26059521
http://dx.doi.org/10.1136/bmjopen-2014-006560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466612/
https://www.ncbi.nlm.nih.gov/pubmed/26059521
http://dx.doi.org/10.1136/bmjopen-2014-006560

Ejemplares similares